Paris will host Targeting Microbiota 2022, the


image: International Microbiota Society – Targeting Microbiota 2022
to see After

Credit: ISM graphic designer

The 9th World Congress on Microbiota Targeting 2022: Towards the Clinical Revolution will be held from October 19 to 21 in Paris and online.

The Targeting Microbiota 2022 congress aims to present the latest microbiota advances in health and disease, as well as all recent innovations and therapeutic strategies. The presidents of the scientific committee: Marvin Edeas, Institut Cochin, INSERM, University of Paris, France, and Peter Konturek, CHU of the University of Jena, Germany, declared: “In order to have a clearer vision of the strategic role of Microbiota, this year, we will bring together many presentations and complementary topics, controversies and clinical advances. We will devote more time to the discussion, primarily on how to deal with the enormous speed to market versus microbiota science.

Among the topics that the ISM will address during the congress:

  • Microbiota dysbiosis in diseases: recent advances
  • Microbiota metabolites: state of the art and perspective
  • Microbiota, Slimming & Slimming: Science or Marketing?
  • Personalized nutrition and microbiota
  • Microbiota in mineral water and hot springs: an unexplored science
  • Role of the microbiota in drug metabolism: towards personalized medicine
  • Targeting Microbiota Dysbiosis: Strategies to Manipulate the Microbiome and Microbiota
  • Brain, behavior, aging and microbiota
  • Microbiota Innovation, Challenges & Sprints
  • Discussion: Microbiota World – Between science and marketing

Among the Microbiota Targeting 2022 hot topics:

Pierre Déchelotte, University of Rouen Normandy, France, will discuss recent findings on the probiotic strain H. alvei HA4597 for weight loss.

The beneficial effects of natural mineral waters on intestinal inflammation and mucosa-associated microbiota will be discussed exclusively by Nicolas Barnich, University Clermont Auvergne, France, to better understand the role of different microbiota profiles in water sources.

Targeting Microbiota 2022 will focus in particular on the extracellular vesicles with Fermin I. Milagro, University of Navarre, Spain. He will present his research on gut microbiota-derived extracellular vesicles on obesity, diabetes and metabolism.

Annalisa Terranegra, Sidra Medical and Research Center, Qatar, will chair a session on personalized nutrition and microbiota. She will present her most recent findings on precision nutrition to modulate the gut microbiota in reproductive health and pregnancy.

François Leullier, University of Lyon, France, will share his recent studies on microbial influence on linear growth. His approaches aim to identify both the bacterial and host genetic and metabolic networks necessary to maintain their mutualistic relationship.

Stephen Lindemann, Purdue University, USA, will discuss manipulation of polysaccharide fiber structure to alter gut microbiota targeting.

Andrés Moya, University of València, Spain, will present recent studies on healthy human gut microbiota in a Mediterranean cohort.

From microbiota innovations who will be presented: Bertrand Routy, University Hospital of Montreal, Canada, will explain how it is possible to target the microbiota in order to treat cancer, by shifting the microbiome towards a more diverse and beneficial bacterial composition and by promoting the response to treatment.

Nathan Price, Thorne HealthTech, USA, will discuss the importance of microbiome interpretation and present new technology for collecting microbiome samples.

Carmen González-Bosch, Universitat de València, Spain, will present the role of short-chain fatty acids in redox signaling in health and disease.

The future of microbiota medicine will also be discussed by Peter C. Konturek, president of the ISM, and Marvin Edeas, president of the scientific committee. They will present and discuss the latest findings on FMT research and strategies to target microbiota – mitochondria.

André Schmidt, University of Basel, Switzerland, will present the use of probiotics and FMT as complementary therapies for depression.

Frank Scheer, Harvard Medical School, USA, will present a proof-of-principle demonstration of the effects of the endogenous circadian system and circadian misalignment on the human oral microbiota. His findings offer translational relevance to people typically exposed to circadian misalignment, including night shift workers and frequent travelers.

Lei Dai, from the Institute of Advanced Technology in Shenzhen, China, will focus on understanding the heterogeneity of host-associated microbial communities.

On October 19, a workshop on Gut Microbiota Assessment & Modulation will be devoted to presenting all the methods of microbiota assessment, as well as the development of pre, pro and post-biotics in order to understand how these formulations can be central to rebalancing and strengthening the microbiome.

You can also submit your abstract before October 10.

For more information on Targeting Microbiota, visit the ISM conference site or follow the hashtag #TargetingMicrobiota.

About the International Society for Microbiota (ISM):

The ISM was born in 2013 after the transformation of the Mitochondria-Microbiota Task Force into a larger group bringing together all the actors and experts working in the field of microbiota. The idea is to bring a new level of thinking and understanding of microbiota science out of the existing classical point of view. Gut and microbiota science is a dynamic, evolving field affected by multiple factors. ISM will bring this dynamic new perspective to accelerate the credible translation of this science into real consumer benefit. ISM also encourages communication and interaction between researchers, physicians, nutritionists, industrialists, food technology and strategic marketing managers through a global microbiota network, including at its annual global meeting. After its last meeting, the ISM published a comprehensive review on Microbiota Medicine: Towards Clinical Revolution in the Journal of Translational Medicine.

Warning: AAAS and EurekAlert! are not responsible for the accuracy of press releases posted on EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.


About Author

Comments are closed.